Arcutis Technologies Q2 product revenue surges
Overview
Arcutis Q2 2025 net product revenue rises 164% yr/yr to $81.5 mln
Company reports net loss of $15.9 mln, an improvement from prior year
FDA approves ZORYVE foam for scalp and body psoriasis, boosting sales
Outlook
Company anticipates Q4 approval for ZORYVE cream 0.05% in children
Company focused on expanding ZORYVE's approved uses
Arcutis advancing pipeline with ARQ-234 for atopic dermatitis
Result Drivers
STRONG DEMAND - Revenue growth driven by increased demand for ZORYVE foam and cream, particularly following FDA approval for new indications
PRESCRIPTION GROWTH - Over 439,000 prescriptions filled for ZORYVE cream 0.3% and 405,000 for ZORYVE foam since launch, reflecting high patient and physician satisfaction
PIPELINE ADVANCEMENT - Continued advancement of ZORYVE and ARQ-234 pipeline, with new studies and regulatory submissions underway
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue |
| $81.50 mln |
|
Q2 Net Income |
| -$15.89 mln |
|
Q2 Basic EPS |
| -$0.13 |
|
Q2 Operating Expenses |
| $96.12 mln |
|
Q2 Operating Income |
| -$14.61 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $20.00, about 23.4% above its August 5 closing price of $15.33
Press Release: ID:nGNX91BvHc
